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Streptococcus pyogenes infects over 700 million people worldwide annually. Immune
evasion strategies employed by the bacteria include binding of the complement inhibitors,
C4b-binding protein (C4BP) and Factor H in a human-specific manner. We recently
showed that human IgG increased C4BP binding to the bacterial surface, which
promoted streptococcal immune evasion and increased mortality in mice. We sought
to identify how IgG promotes C4BP binding to Protein H, a member of the M protein
family. Dimerization of Protein H is pivotal for enhanced binding to human C4BP. First,
we illustrated that Protein H, IgG, and C4BP formed a tripartite complex. Second,
surface plasmon resonance revealed that Protein H binds IgG solely through Fc, but
not Fab domains, and with high affinity (IgG-Protein H: KD = 0.4 nM; IgG-Fc-Protein
H: KD ≤ 1.6 nM). Each IgG binds two Protein H molecules, while up to six molecules
of Protein H bind one C4BP molecule. Third, interrupting Protein H dimerization either
by raising temperature to 41◦C or with a synthetic peptide prevented IgG-Protein H
interactions. IgG-Fc fragments or monoclonal human IgG permitted maximal C4BP
binding when used at concentrations from 0.1 to 10 mg/ml. In contrast, pooled human
IgG enhanced C4BP binding at concentrations up to 1 mg/ml; decreased C4BP binding
at 10 mg/ml occurred probably because of Fab-streptococcal interactions at these high
IgG concentrations. Taken together, our data show how S. pyogenes exploits human IgG
to evade complement and enhance its virulence. Elucidation of this mechanism could aid
design of new therapeutics against S. pyogenes.
Keywords: the complement system, Streptococcus pyogenes (S. pyogenes), immunoglobulin G (IgG), infectious
disease, protein complex, protein stability, protein-protein interaction, stoichiometry
INTRODUCTION
Streptococcus pyogenes is one of the clinically most important gram-positive human pathogens.
The bacteria cause a spectrum of infections, ranging from mild and superficial infections to life-
threatening systemic conditions (1–3). Every year, more than 700 million S. pyogenes infections
occur worldwide with more than 500,000 deaths (4). Natural infection caused by this bacterium
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is restricted to humans. Group A streptococci have developed
complex virulence mechanisms to avoid immune recognition
and activation (5). One of the most prominent virulence factors
are the surface proteins of the M protein family. M proteins
have antiphagocytic properties, bind various host proteins and
are involved in adherence and invasion of host cells (6–12). M
proteins are also used to classify streptococci, and to date more
than 200 different strain groups have been identified (13).
Protein H is a surface virulence factor that belongs to the
family of M-proteins (14). It binds to a variety of human serum
proteins, such as albumin, complement inhibitors including
Factor H (FH) and C4b-binding protein (C4BP), and the Fc
portion of immunoglobulins (8, 11, 15–17). Binding of C4BP and
FH to the surface of S. pyogenes leads to a significant increase in
virulence in vivo (18).
The complement system is one of the first lines of defense
against invading microbes. The complement cascade comprises
over 30 proteins that can mark (opsonize) targets such as
pathogens, debris or foreign cells for removal by phagocytes.
Complement activation also results in formation of pores that
can directly lyse eukaryotic cells or gram-negative bacteria
(19, 20). Since this cascade can potentially lyse host cells
and cause excessive inflammation, tight control is pivotal. In
addition to several membrane-bound complement inhibitors that
protect the host cells from over-activation of complement, two
major inhibitors regulate the cascade in solution: C4BP and
FH [reviewed in (21, 22)]. C4BP inhibits the classical and the
lectin pathways of complement, while FH inhibits the alternative
pathway. One molecule of C4BP comprises of seven identical α-
chains and a unique β-chain (23). Most interactions with ligands
occur via the α-chains (22). C4BP acts as a cofactor to factor I (FI)
and inactivates both soluble and cell-bound C4b, thus preventing
the formation as well as accelerating the decay of the classical C3-
convertase (24, 25). Unfortunately, some pathogens have evolved
to hijack this host-protection mechanism [reviewed in (26)]. By
coating themselves with complement inhibitors, microbes limit
complement activation and evade immune recognition, thus
enabling them to cause invasive infections (27).
Similar to M proteins, Protein H has a dimeric coiled-
coil structure (28, 29). The binding of host serum proteins
is dependent on the dimeric state of the protein, which is
influenced by temperature and the presence of certain ligands
such as IgG (28, 30). Recently, we showed that C4BP binding
to S. pyogenes is enhanced by human IgG (31). Increased
C4BP binding mediated by IgG resulted in decreased phagocytic
elimination of bacteria and a dramatic increase in mortality in
experimental streptococcal infections in mice. The molecular
basis of IgG enhancement of C4BP binding remains unclear. In
this study we focused on protein-protein interaction between
human IgG, C4BP, and Protein H. We characterize the complex
formation between the three proteins. Furthermore, we describe
the influence of temperature on the molecular structure of
Protein H, the effect on intramolecular dimerization and
the implications for ligand binding, bacterial interaction and
complement evasion.
Contrary to the conventional opsonic and protective functions
of IgG against bacteria, here, we elucidate the molecular basis
whereby IgG enhances C4BP binding to Protein H, which
paradoxically enhances Group A streptococcal virulence.
MATERIALS AND METHODS
Bacteria and Culture Conditions
Streptococcus pyogenes AP1 (from the WHO Collaborating
Center for Reference and Research on Streptococci, Prague,
Czech Republic) and its isogenic mutant BMJ71 lacking Protein
H and M protein (32) was grown in Todd-Hewitt broth (Oxoid)
at 37◦C if not stated otherwise and 5% CO2 overnight. To ensure
maximal expression of virulence factors, overnight cultures were
subsequently diluted to OD600 = 0.1 in fresh Todd-Hewitt broth
and further incubated at 37◦C in 5% CO2 to an OD600 of 0.3–
0.4. Prior to use, bacteria were washed with PBS and adjusted to
desired OD600.
Proteins and Antibodies
Fab fragments of pooled human IgG were purchased from
Calbiochem, pooled human Fc fragments from Athens Research,
human IgG (IVIG; Kiovig) from Baxalta. Immunoglobulins were
purchased from Sigma (IgA, IgM, IgG3, and IgG4), Amgen
(denosumab), Athens Research and Technology (IgG1, IgG2),
Abcam (IgD), Thermo Fisher (IgE), and goat control IgG from
Molecular Innovations. Denosumab (Amgen) is a monoclonal
hu-IgG2 antibody that recognizes human RANKL and is used
to treat osteoporosis, but does not recognize S. pyogenes (31).
For flow cytometric analysis, the following Abs were used: mouse
anti–hu-C4BP MK104 (33) coupled to biotin, goat anti human
IgG (H+L)−647 (Invitrogen). Streptavidin PE (eBioscience) was
used to detect MK104-biotin. Human C4BP was purified from
human plasma; Protein H was expressed and purified from E.
coli, all according to previously described protocols (11, 34).
The AHP peptide was a gift from Prof. Lars Björck (35). α1-
antitrypsin [α1AT; a gift of the late Prof. Bertil Laurell (36)]
was used as a negative control for binding experiments. Plasma
purified C4BP preparations of 2 mg/ml contained between 2 and
10µg/ml human IgG, as determined by a sandwich ELISA for
human IgG.
Radioactive Labeling of Proteins With
125Iodine
Purified proteins C4BP or Protein H (40 µg) were labeled with
each 18.5 MBq (Hartmann Analytics) in the presence of 2
iodobeads (Pierce, Thermo Fisher) for 15min according to the
manufacturer’s instruction. Free radioactivity was removed using
a PD-10 gel filtration column (GE Healthcare) and eluted with
500 µl PBS. Fractions containing the majority of radioactivity
(usually 3) were pooled and used for experiments. For storage at
−20◦C 500 µl glycerol was added. Specific activity was measured
by analyzing 2 µl of the glycerol stock in a Wizard2 gamma
counter (Perkin Elmer). 125I-C4BP had an average specific
activity of about 30.000 cpm/µl, while 125I-Protein H had in
average 75.000 cpm/µl.
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Binding of 125I- Protein H, 125I-C4BP to
Purified Proteins or Bacteria
Purified proteins (C4BP, IgA, IgD, IgE, IgG, IgM, IgG1, IgG2,
IgG3, and IgG4) were diluted to 5µg/ml in PBS and immobilized
onto microtiter plates (Maxisorp breakapart, Nunc) at 4◦C
overnight. The plates were washed 3 times with wash buffer
(50mM Tris pH 8.0, 150mM NaCl, 0.1% Tween 20) and
non-specific binding sites were blocked with 3% fish gelatin
(Norland Products) in wash buffer. 125I- labeled Protein H (50
kcpm) was diluted in binding-PBS (PBS supplemented with
0.1% Tween-20 and 0.1% BSA) and added to the immobilized
proteins; in case of immobilized C4BP, indicated amounts of
IVIG were added as stated in the individual experiments. After
overnight incubation at 4◦C and subsequent washing, using a
Wizard2 gamma counter (Perkin Elmer) radioactivity in the wells
was measured. 125I- labeled C4BP (500 Kcpm) was added to
5∗105 bacteria in a final volume of 100 µl in the presence of
indicated amounts of different IgG preparations and incubated
at 37◦C for 1 h. Bacteria were washed thrice with PBS prior
to counting bacteria-associated radioactivity using a Wizard2
gamma counter (Perkin Elmer).
Complement Deposition and IgG Binding
Assays
Bacteria (1∗106/sample) were incubated in 100µl PBS containing
10% normal human serum (NHS), 20 µg purified C4BP or
10% human (hu-) C4BP transgenic (tg) mouse serum in the
presence or absence of 200 nmol of the synthetic peptide
QKQQQLETEKQISEASRKS (AHP) for 30min at 37◦C in 5%
CO2. Bacteria were washed thrice with PBS before and after
each staining step. Bacteria were subsequently stained to detect
surface-bound IgG and C4BP with either anti-C4BP or anti-
human IgG, respectively. Bacteria were visualized by staining
with 1µM cell trace violet (Invitrogen). Samples were analyzed
using a Cytoflex flow cytometer (Beckman Coulter). Negative
controls included unstained bacteria as well as bacteria stained
only with streptavidin-PE.
Native Protein Agarose Gel Electrophoresis
To form protein complexes, C4BP, IgG, and Protein H were
mixed in a molar ratio of 1:10:10 in PBS for 1 h at 37◦C prior
to loading. All proteins in different lanes were loaded in same
quantity, either directly loaded onto gels (single proteins) or pre-
incubated together in PBS for 1 h at 37◦C (for all mixtures).
Agarose-gel electrophoresis was run for 3–4 h at pH 8.6 in 75
mM-sodium barbital buffer on a flexible polyester film Gelbond
TM as described previously (37). Subsequently, the fixed agarose
gel was stained with Coomassie blue.
Nanoparticle Tracking Analysis (NTA)
NTA is used to study complex formation of proteins. NTA
records the scattered light from objects in solution, where after
the NTA software tracks the individual scattered lights over time.
By using the Stokes-Einstein equation the size of the individual
objects can be determined (38). IgG (130 nM), C4BP (130 nM),
and Protein H (800 nM) were mixed and injected into the sample
cell. The sample was monitored using a NanoSight LM10 HS,
equipped with a 405 nm laser; 30 s videos were collected at
different time points and the data analyzed using NTA software.
Electron Microscopy
The presence and location of individual molecules was analyzed
by negative staining electron microscopy, as described previously
(39).To visualize the aggregation of C4BP and protein H (molar
ratio 1:10), both proteins were co-incubated in the presence
or absence of 1 mg/ml IVIG for 1 h at 37◦C. To analyze self-
assembly, 10 µg of Protein H was incubated either at 4 or
37◦C before adsorbtion to the grids. The grids were rendered
hydrophilic by glow discharge at low pressure in air. Five
microliter aliquots were adsorbed onto carbon-coated grids for
1min. After washing with two drops of water, the samples were
stained with two drops of 0.75% uranyl-formate. Specimens
were examined using a Philips/FEI CM 100 electron microscope
operated at an accelerating voltage of 80 kV; images were
recorded with an OSIS Veleta, side-mounted digital slow scan 2 k
× 2 k CCD camera system using DigitalMicrographTM software.
The area of protein complexes and the length of Protein H
molecules was measured in Adobe Photoshop CS6. Proteins,
which were in closer contact than 30 nm or less, were considered
to interact or to be colocalized.
Complex Formation for Macroscopic
Analysis
C4BP (0.15 nM) was mixed with IgG (0.75 nM) and Protein H
(1.5 nM) in a break-apart 8 well-strip. As controls, combinations
of only two proteins were also prepared as indicated. Pictures
were taken at room temperature immediately after combining the
proteins without any incubation time.
Size Exclusion Chromatography
All size exclusion chromatography was performed using an
Äkta explorer system (GE Healthcare) employing a Superose 6
10/30 column using PBS as eluent; 0.6 ml/min flow at ambient
temperature. Proteins were incubated together in PBS for 30min
at room temperature at indicated ratios before analysis or left
untreated as single protein controls. Individual proteins or
protein mixtures were injected in 200 µl PBS and the absorbance
at 280 nm subtracted by 320 nm (indicated as Abs280−320nm)
was recorded to identify the elution profile. To analyze Protein
H and AHP interaction absorbance 215 nm was measured
since the peptide absorbs only weakly at 280 nm. The binding
stoichiometry and KD were estimated by fitting equation 1 to
the data




where A is the observed integrated absorbance of the peak
corresponding to the free form of the varied proteins, CL, the total
concentration of the varied protein, CB, the total concentration
of binding sites on the constant protein, and ε the extinction
coefficient. The stoichiometry was obtained as the value of the
ratio CB/CP that produced the lowest error square sum, where
CP is the total concentration of the constant protein. The size
exclusion column was calibrated using the high molecular weight
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(HMW) gel filtration calibration kit (GE Healthcare) to estimate
the molecular weight by size exclusion.
Surface Plasmon Resonance (SPR)
All SPR experiments were conducted on a Biacore 3,000 system
(GEHealthcare). IgG was immobilized by injecting 30µg/ml IgG
in 10mM sodium acetate pH 5.1 buffer at a flow rate of 5 µl/min,
onto channel 2, 3, and 4 of an EDC/NHS activated CM5 chip
(GE Healthcare). Channel 1 served as an EDC/NHS activated
blank channel. All four channels of the chip were blocked
with ethanolamine before affinity measurements. Association
and dissociation measurements were performed in 10mM
Hepes/NaOH, 150mM NaCl, 3.4mM EDTA, 0.005% Tween 20
(HBS-EP) buffer (GEHealthcare) at 30µl/min flow rate. The chip
was regenerated with 300 µl 10mM glycine/HCl pH 2.7 between
runs. Protein H was diluted in HBS-EP buffer (GE Healthcare).
A measurement with 10 h dissociation time was used for koff
determination. Experiments with different concentrations of
Protein H were set up with short dissociation times in between
experiments for kon determination. BIAevaluation Software was
used to fit the data to 1:1 Langmuir kinetics using the mode
“Kinetics Separate kon/koff.” The SPR for IgG-Fc were conducted
in similar way except that in order not overestimate KD the
fitting was done with a fixed value of koff (1∗10−4 s−1), since the
obtained values for koff spread over 3 orders of magnitude for
individual experiments (2.6∗10−4−3.8∗10−7 s−1).
Thermophoresis
Because C4BP interactions are difficult to analyze using SPR due
to avidity effects (6–7 identical α-chains), we also performed
analysis by thermophoresis. The thermophoresis instrument,
Monolith NT.115, was used for the KD determination. Protein
H was labeled with Alexa-488 succinimidyl ester in phosphate
buffer followed by gel filtration to remove free dye. All
experiments were conducted inMST buffer (50mMTris-HCl pH
7.4, 150mM NaCl, 10mM Mg Cl2, 0.05 % Tween-20). Samples
contained Protein H and C4BP. Protein H concentration was
kept constant at 0.5 nM, while C4BP was used at 16 different
concentrations. The measurements were conducted at 37◦C,
100% LED power, and 80 or 100 % MST power. Equation 2 was
fitted to the data:
S = S1 + S2∗[L]/([L]+KD)
Where S1 is the thermophoresis signal for free ProteinH, S2 is the
signal for the complex, and [L] = (0.5(CL-CH-KD)+
√
(0.25(CL-
CH-KD)2+CLKD)), where CL is the total concentration of
the protein being varied, and CH, the total concentration of
Protein H.
Calculating Stoichiometry
To determine stoichiometry of the C4BP-IgG-protein complex,
we premixed C4BP and Protein H (Figures 4A,C,E) or Protein
H and IgG (Figures 4B,D,F) in different molar ratios. The
concentration of one reaction partner was always kept constant
while the amount of the other component was increased
gradually as indicated. For every sample (indicated with different
colors in the elution diagram) we performed SEC to identify
the unbound amount of either Protein H (Figure 4A) or IgG
(Figure 4D). AUC of the peaks of unbound protein were then
plotted against the total amount of that protein (Figures 4B,E).
This resulted in a binding curve allowing us to calculate a KD
value as well as the binding sites for the indicated proteins.
Aggregation of Bacteria
Bacterial aggregation was measured according to a previously
published protocol (35) with the following modifications:
bacteria were grown overnight at 30, 35, 37, and 41◦C in
13ml sample tubes filled with 10ml Todd Hewitt broth.
Immediately after removing the tubes form the incubator,
bacteria were gently shaken (Vortex Genie 2, intensity 2, 3 s)
and OD600 was measured. To assess total amount of bacteria
and exclude growth differences, samples were subsequently
vortexed (vortex, intensity 10, 10 s) and OD600 was measured
(WPA spectrophotometer). To calculate % bacterial dispersion,
OD600 before vortexing was divided by OD600nm after vortexing
and multiplied by 100 ([OD600nm before vortexing/OD600nm
after vortexing] ∗ 100). To assess growth differences due
to temperature, we compared OD600nm after vortexing and
found that all bacteria showed identical ODs in all tested
temperatures after vortexing. Analysis of IgG binding to bacteria
grown at different temperatures showed that Protein H was
ubiquitously expressed.
Serum Preparation
Human serumwas prepared according to (40). Human blood was
allowed to clot for 30min before centrifuged two times for 7min
at 700 × g. Serum was aliquoted and stored at −80◦C. Mouse
serum was prepared as described before (18). Animals were
anesthetized with Isoflurane, and blood was collected by cardiac
heart puncture. Blood samples were kept on ice for 30min and
allowed to clot before centrifuging for 10min at 1,700 g and
4◦C. Serum was separated, aliquoted, and frozen immediately at
−80◦C until use.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 7.0b. To
test for significance, we used 1-way or 2-way ANOVA analysis
with Bonferroni’s or Tukey’s post-test tests or student’s t-test as
indicated. P < 0.05 was considered to be significant.
RESULTS
Protein H is a surface bound virulence factor known to bind the
Fc region of human IgG. In addition to IgG, Protein H also binds
to C4BP. Surprisingly, despite overlapping binding sites for IgG
and C4BP on Protein H, we observed that human IgG increased
binding of C4BP to Protein H, protecting S. pyogenes from
immune recognition and clearance (31). However, the details of
the molecular interactions between Protein H, IgG and C4BP
are not completely understood. Using 125-I labeled Protein H we
confirmed that IgG is the most prominent class of Ig that binds
to Protein H. We detected low amounts of IgA binding, but no
significant binding of the remaining Ig classes (Figure 1A). In
addition, Protein H bound to all four sub-classes of IgG. We
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FIGURE 1 | Protein H binds human IgG and C4BP. Protein H binds to IgG and to a minor extent also IgA, but not other classes of immunoglobulins (A). All four tested
subclasses of human IgG bind Protein H in a similar manner with a preference for IgG3 (B). Protein H, C4BP and IgG, alone or in combinations (C), as well as
Denosumab and IgG-Fc together with C4BP and Protein H (D) were separated on a native horizontal agarose gel and stained with Coomassie blue. Arrows indicate
protein complexes which did not migrate. The mean (SD) of three separate experiments is shown in (A) and (B). One representative experiment of at least three
repeats is shown in (C) and (D). *** p < 0.001 and **** p < 0.0001 assessed by 1-way ANOVA (A) and (B) with Bonferroni’s post-test compared to α1 anti-trypsin
(α1AT), an irrelevant protein control.
noted similar binding to IgG1, IgG2, and IgG4, while slightly
higher binding to IgG3 was observed (Figure 1B; p < 0.0001
compared to IgG1/IgG2; p= 0.0004 compared to IgG4).
In order to further define if IgG interacted with Protein
H and/or C4BP, we performed native protein agarose gel
electrophoresis, which does not disrupt protein-protein
complexes. Proteins are separated according to their native
charge, so migration can occur in either direction. Proteins may
appear as a distinct band (as in the case of C4BP; Figure 1C,
lane 7) or as a diffuse smear in the case of IgG (Figure 1C, lane
5) because (polyclonal) human IgG (IVIG) is a heterogenous
mixture of molecules derived from >1,000 donors, each with a
unique pI and glycosylation pattern. The following combinations
of proteins were separated: Protein H with IgG; Protein H with
C4BP; C4BP with IgG, and all the three proteins together. When
compared with the migration pattern of the proteins individually
(Figure 1C; lanes 5, 6, and 7), agarose electrophoresis revealed
that IgG interacted with Protein H but not with C4BP (lanes 4
and 3, respectively). Further, C4BP interacted with Protein H
alone (lane 2). As expected, IgG formed a complex with Protein H
and C4BP, which resulted in large complexes that were retained
in loading pockets (lane 1). Migration patterns of protein
complexes differ from proteins migrating individually due to
changes in form, size, and charge, which led to the conclusion
that Protein H interacts both with C4BP and IgG, however
C4BP does not interact with IgG. We repeated this experiment
using IgG-Fc fragments as well as a monoclonal human IgG2
(Denosumab) to reduce the influence of Fab mediated binding
to Protein H from pooled human IgG (Figure 1D). Differences
were particularly obvious in lanes 10 and 11 (IgG-Fc and
Denosumab) comparing the “only antibody” lanes the to the
IVIG lane in Figure 1C lane 5. IgG-Fc fragments are derived
from pooled human IgG, thus the four distinct bands may
reflect different IgG subclasses and/or different Fc glycosylation
patterns. In contrast, lane 10 shows a distinct band instead of a
smear. This is because Denosumab is a recombinantly expressed
monoclonal IgG2 antibody with a single glycosylation pattern.
We used Denosumab as a source of a recombinant human
monoclonal antibody that does not recognize S. pyogenes. The
interactions between IgG and Protein H as well as C4BP and
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FIGURE 2 | C4BP, Protein H and IgG form large complexes in vitro. (A) Electron microscopy images of negative stained protein complexes formed between IVIG,
Protein H and C4BP or only C4BP and Protein H (B). (C) Protein H together with C4BP and IgG forms large complexes in solution, which are visible macroscopically.
C4BP, IgG and Protein H were co-incubated for indicated time and analyzed by nanoparticle tracking analysis (NTA) to estimate complex size at a given time (D) or the
concentration change of object size over time (E). Bars indicate 50 nm. Representative experiments of at least 3 repeats are shown.
Protein H are almost identical. Protein H interacts with both
IgG-Fc and denosumab (lanes 6 and 7), C4BP does not bind to
IgG-Fc or Denosumab (lanes 4 and 5) but to Protein H (lane 3).
All three proteins together form an insoluble precipitate in the
loading pocket (lanes 1 and 2; indicated by arrows) as already
seen with IVIG in Figure 1C. The distinct band in the upper part
of lane 1 Figure 1D is attributed to an excess of Denosumab. Of
note, this band is less prominent compared to lane 10 despite
the same amounts of IgG loaded. A similar band for IgG-Fc does
not appear in lane 2, because we used the same molar equivalent
of IgG-Fc as intact IgG; Fc is only a third of the mass of IgG,
resulting in a signal that is about two-thirds less intense. Taken
together, we found similar interaction patterns with Protein H
and C4BP and IgG independent on the type of IgG (polyclonal,
monoclonal or IgG-Fc) used. Thus, our data shows that IgG-Fc
mediates the increased C4BP binding to Protein H (Figure 1D).
Protein H Forms Large Complexes With
C4BP and IgG
We observed, that Protein H together with IgG and C4BP, formed
complexes which remained in the loading pockets of the agarose
gel (arrows in Figures 1C–D). We sought to analyze this complex
further employing electron microscopy. The analysis showed
large tripartite complexes of Protein H, IgG, and C4BP covering
up to 35,000 nm2 (Figure 2A). In the absence of IgG, C4BP
and Protein H complexes covered a maximal area of 2,400 nm2
(Figure 2B). All three proteins (molar ratio of C4BP:Protein
H:IgG 1:10:5) together formedmacroscopically visible aggregates
(Figure 2C, first well) while any combination of only 2 proteins
showed no visible precipitation. To further analyze the complex
between protein H, IgG and C4BP we performed nanoparticle-
tracking analysis (NTA). We found that the concentration of
larger particles increased over time, while the numbers of smaller
complexes decreased (Figure 2D). Particle size analysis showed
that smaller particles rapidly decreased in concentration, while
larger particles increase over time and finally exceeded the limit
of analysis (Figure 2E). Control experiments with NTA shows
that any other combination of proteins, at the concentration and
ratio used in this experiment does not form large aggregates
(Figure S1). C4BP alone or in combination with either IgG or
Protein H is stable and does not show any changes in size or
concentration over a time period of 1.5 h (Figures S1A–C). IgG
alone does not scatter enough light to be detected with NTA
(Figure S1D), and does not form large aggregates in the presence
of Protein H (Figure S1E).
We then aimed to determine the KD values for the interaction
of IgG-Protein H and C4BP-Protein H. Surface plasmon
resonance analysis of IgG-Protein H revealed a strong interaction
with a KD value of 0.4 nM (Figure 3A). C4BP is made of 7
identical α-chains each of which contains potential binding sites
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FIGURE 3 | Protein H binds C4BP and IgG (-Fc) with high affinity, but not
IgG-Fab. To define equilibrium affinity constants for IgG-Protein H (A) and
C4BP-Protein H (B) interaction, surface plasmon resonance and
thermophoresis analysis were performed, respectively. Surface plasmon
resonance analysis revealed that Protein H does not interact with IgG-Fab (C)
but binds IgG-Fc strongly (D). Red dots represent individual measurements,
black lines are corresponding fits.
for Protein H.We applied thermophoresis to estimate the affinity
between Protein H and C4BP, which revealed a KD of 180 nM
(Figure 3B). Protein H did not interact with IgG Fab fragments
(Figure 3C). Protein H bound to Fc fragments derived from
pooled IgG with a KD of <1.6 nM, which was similar to the
interaction between Protein H and intact IgG (Figure 3D). This
indicates that IgG in human serum recognizes Protein H on S.
pyogenes through its Fc domain.
Stoichiometry of C4BP-Protein H and
Protein H-IgG
Since C4BP has several potential binding sites for Protein
H, we sought to identify the stoichiometry of the binding
between Protein H and C4BP as well as Protein H and
IgG. We performed size exclusion chromatography (SEC) of
C4BP-Protein H mixtures at different molar ratios (Figure 4A).
Subsequent analysis of free Protein H revealed the stoichiometry
of the interaction (Figure 4B): one molecule C4BP can bind
up to 26 ± 2 Protein H monomers. At room temperature,
presumably two Protein H dimers bind to one α-chain of C4BP
(Figure 4C). Similarly, we analyzed the Protein H-IgG complex
by SEC (Figure 4D). Analysis of free Protein H showed that one
IgGmolecule bound a single monomer of Protein H (Figure 4E).
We therefore speculate that a Protein H dimer could bind two
IgGs (Figure 4F).
Temperature Influence on Protein H
Dimerization
To assess the influence of temperature on Protein H we
performed SEC on Protein H at different temperatures. At 8◦C
and 28◦C we found that Protein H eluted at 12.9ml, while
at 41◦C protein eluted later at 15.9ml (Figure 5A). Because
larger proteins elute earlier, Protein H appeared to elute as
a dimer at 8◦C and 28◦C, but as a monomer at 41◦C. To
confirm this, we calibrated the column using standard marker
proteins and calculated KAV values to estimate the molecular
weight of Protein H (Figure 5B). At lower temperatures, Protein
H appeared to have a size of ≈750 kDa, while at 41◦C the
size estimate was ≈350 kDa, confirming the elution as dimers
and monomers, respectively (Figure 5B, table). The apparent
discrepancy of theoretical or calculated (42 kDa) and observed
MW (350 kDa) of monomeric Protein H is because of the
elongated shape of the protein. Globular proteins are used
for calibration, while Protein H has a cylindrical, needle-like
shape. Yet, an increase in size by a factor of two in purified
preparations of Protein H strongly suggests the formation of
a dimer.
We then sought to determine whether dimerization of Protein
H also affected IgG binding. Using SEC analysis, we found that
monomeric Protein H at 41◦C did not bind IgG (Figure 5C).
The elution curve of Protein H incubated with IgG overlapped
with the elution curves of IgG or Protein H alone. As a
control, the elution curve of dimerized Protein H at 8◦C has
been superimposed. Similarly, binding of IgG-Fc to monomeric
Protein H did not occur at 41◦C (Figure 5D); elution curves for
the single proteins and the co-incubated samples were similar.
Taken together, these data show that only dimeric, but not
monomeric Protein H binds human IgG. Electron microscopy
analysis of isolated Protein H showed an increase in length of
individual Protein H molecules with a decrease in temperature.
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FIGURE 4 | Binding sites for Protein H on C4BP and IgG. C4BP-Protein H and Protein H-IgG interactions were analyzed in combination by SEC on a Superose 6
column. (A) C4BP-Protein H complexes were formed in PBS with 0.25 nmol C4BP and varying amounts of Protein H (indicated by molar ratio). (B) AUC of free
Protein H (eluted at 13.74ml) was plotted against total Protein H concentration (n = 13). (C) Analysis revealed that one molecule of C4BP can bind up to 26 ± 2
Protein H monomers and is shown diagrammatically. (D) Protein H-IgG complexes were formed in PBS with 2 nmol Protein H and varying amounts of IgG (indicated
by molar ratio). (E) AUC of free IgG (eluted at 16.19ml) was plotted against total IgG concentration (n = 15). (F) Analysis revealed that one Protein H dimer can bind
up to two IgG and is represented diagrammatically. In (B,D) blue dots represent individual measurements, black lines are corresponding fits. Every curve or data point
represents an independent experiment. In (A,D) representative elution curves are displayed, while all experiments were used for the analysis in (B,E).
At 37◦C (Figure 5E) ProteinH appeared to be shorter than at 4◦C
(Figure 5F). Size evaluation of more than 500 molecules showed
that Protein H has an average length of 50 nm at 37◦C, but about
80 nm at 4◦C (Figure 5G). Because the interaction site for Protein
H is not located at the N-terminal tip of the protein but within the
first third of the protein, dimerization did not double the length,
but was less than the sum of the two proteins. This supports the
notion that two Protein H molecules interact with each other in
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FIGURE 5 | Protein H dimerization is temperature dependent and crucial for IgG binding. (A) Size exclusion chromatography (SEC) analysis of 5 nmol Protein H at
different temperatures using a Superose 6 10/30 column. (B) Calibration of SEC on a Superose6 10/30 column using high molecular weight marker proteins to allow
estimation of protein sizes. For size estimation of mono- and dimers of Protein H, KAV values were calculated using the formula KAV = (Ve-Vo)/(Vt-Vo) with Ve = elution
volume in ml; Vo = void volume (estimated with blue dextran 2,000 = 8.67ml) and Vt = total column volume (estimated by salt peak = 22.36ml). (C,D) SEC analysis
of 5 nM Protein H with equimolar amounts of IgG’s at different temperatures using a Superose6 10/30 column. Protein H does not bind denosumab (C) or pooled
IgG-Fc (D) at 41◦C. As a reference for Protein H dimers, 4◦C run of Protein H was inserted into both diagrams. Electron microscopy images of negative stained Protein
H at 37◦C (E) and 4◦C (F). (G) Size distribution of Protein H molecules at different temperatures. Representative experiments of at least 3 independent repetitions are
shown. In (E–G) more than 500 molecules for each temperature from different areas on several microscopy grids were analyzed. Bar in (F) indicates 50 nm.
an antiparallel orientation, since a parallel interaction would not
lead to an increase in length.
Since Protein H-Protein H interaction is supposed to be
pivotal for adherence to other bacteria causing aggregation and
increased virulence (35), we asked if temperature had a similar
effect on bacterial aggregation. We inoculated Todd Hewitt
broth with S. pyogenes AP1 and incubated it overnight either
at 35◦C, 37◦C, or 41◦C. We then measured the OD600 of the
medium and compared it to the OD600 after vortexing the
cultures thoroughly ([OD600nm before vortexing/OD600nm after
vortexing] ∗ 100). We found that at 35◦C and 37◦C about
70 % of the bacteria aggregated, while at 41◦C all bacteria
remained dispersed (Figure 6A, red bars). Cultures of S. pyogenes
BMJ71 that lacked Protein H showed no aggregation at all
tested temperatures (Figure 6A, blue bars). Of note, the absolute
OD600nm after vortexing of the different cultures were similar,
indicating no growth defect of the mutant strain or the wild type.
IgG binding experiments performed at room temperature with
wild-type bacteria grown at the before mentioned temperatures
showed similar Protein H expression at all temperatures tested.
Thus, the difference in aggregation was not the result of altered
expression of Protein H or a difference in growth.
A previous report showed that a synthetic peptide with a
sequence of QKQQQLETEKQISEASRKS (aggregative Protein H
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FIGURE 6 | AHP does not disrupt dimers formed by purified soluble Protein H but increases C4BP binding to intact bacteria. (A) S. pyogenes AP1 grown at different
temperatures showed aggregation at 35◦C and 37◦C. Bacterial dispersion is significantly decreased for AP1 (red bars) at 35◦C compared with 30◦C and 41◦C as
well as at 37◦C compared with 30◦C and 41◦C. Isogenic mutant BMJ71 lacking Protein H (blue bars) shows similar absorption at all temperatures and does not
aggregate. (B) SEC analysis using a Superose 6 10/30 column was performed on 10 nmol Protein H in the presence or absence of 100 nmol of a dimer inhibiting
peptide (AHP). AHP does not prevent dimerization of Protein H. (C) AHP (100 nmol) increased C4BP binding to 5*105 S. pyogenes significantly without altering IgG
binding levels. (D) C4BP binding to S. pyogenes is increased in the presence of 100 nmol AHP both in mouse (ms) serum and for purified C4BP. (E) Presence of
IgG-Fc or monoclonal human IgG2 increases 125 I-labeled C4BP binding to Protein H independent of IgG concentration, while increasing concentrations of IVIG
beyond 1 mg/ml decreases C4BP binding. Representative experiments of at least 3 repeats are shown. *p < 0.05, ***p < 0.001, and ****p < 0.0001 assessed by a
2-way ANOVA with Tukey’s post-test (A,D,E) or a student’s t test (C). Comparison of significance in (A) was performed for different temperatures within a strain (blue
bars and red bars separately).
peptide 150–168; AHP) blocked binding of purified Protein H to
intact bacteria and also prevented bacterial aggregation, similar
to temperatures above 37◦C (35). We performed SEC analysis of
Protein H at room temperature (23◦C, where Protein H exists
as a dimer) in the presence and absence of AHP, to analyse the
influence of the peptide on Protein H dimerization. Interestingly,
the addition of the inhibitory peptide did not change the elution
curve of Protein H even at a 10 molar excess of AHP (Figure 6B).
This indicates that AHP does not interrupt dimer formation
between soluble Protein H molecules.
We then incubated S. pyogenes AP1 in NHS in the presence
and absence of AHP and analyzed C4BP and IgG binding. To our
surprise, we found that in the presence of AHPC4BP binding was
increased significantly bymore than 2-fold while IgG binding was
unaffected (Figure 6C). This effect could be due to more Protein
H dimers available to bind to C4BP instead of to other Protein
H dimers. To see, if complement deposition on bacteria affected
C4BP binding in the presence or absence of AHP, we repeated
the experiment with hu-C4BP tg mouse serum or C4BP purified
from human serum (Figure 6D). In fact, AHP had a similar effect
on C4BP binding to S. pyogenes strain AP1 independent on the
source of C4BP, excluding effects from complement deposition.
The presence of peptide increased C4BP binding to bacteria
2–2.5 fold.
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FIGURE 7 | Protein H structure influences ligand binding and interbacterial interaction. Temperature-dependent dimerization allows various interactions of Protein H.
(A) At temperatures of 37◦C and above the majority of Protein H is monomerized and cannot bind any ligands (incl. C4BP). (B) Upon decrease of temperature,
increasing numbers of Protein H homodimers form and allow interaction with other molecules (left side). Beside low temperatures, IgG binding can stabilize Protein H
homodimers even at high temperatures so that Protein H retains its binding capacity to different ligands (right side). (C) Protein H homodimers do not only bind to
ligands, but also allow homo-tetramer formation to promote interbacterial interaction. Protein H monomers however cannot facilitate bacteria-bacteria interactions.
Similar to ligand binding, lower temperature and presence of IgG at high temperatures stabilize Protein H dimers allowing for tetramer formation (right side). An
increase of temperature as well as absence of IgG a high temperature causes Protein H monomerization and loss of function. AHP also causes loss of protein-Protein
H interaction (tetrameric state reduced to dimeric state) and can at large molar excess also cause monomerization of Protein H.
We previously reported that C4BP binding to Protein H
peaked at 1 mg/ml, but rather surprisingly, decreased at higher
IgG concentrations (31). We asked if this effect was specific
for pooled human IgG (IVIG) or also occurred with IgG-
Fc or monoclonal human IgGs. Thus, we tested 125I-labeled
C4BP binding to S. pyogenes in the presence of increasing
amounts of IVIG, IgG-Fc or monoclonal human IgG. Unlike
IVIG, neither IgG-Fc nor monoclonal IgG induced a decrease
of 125-I C4BP binding to Protein H at high concentrations
(10 mg/ml) (Figure 6E). Consistent with previous observations
(31), we observed decreased C4BP binding to S. pyogenes at 10
mg/ml IVIG.
At temperatures >37◦C Protein H on the bacterial surface
is mainly monomeric (Figure 7A), thus unable to bind ligands.
Stable Protein H dimers capable of binding its ligands occur
at lower temperatures or in the presence of human IgG
Fc domains (Figure 7B). We hypothesize that Protein H
mediated adherence of S. pyogenes to human tissues or the
formation of bacterial aggregates is dependent on dimerization
of Protein H (Figure 7C).
DISCUSSION
In this study we show that C4BP can interact with Protein H
and human IgG in a 1:13:26 molar ratio to form very large
insoluble complexes (> 5 MDa) (Figures 1, 4). We also found
that dimerization of Protein H is favored at lower temperatures
(Figure 5A). Importantly, ligand binding is exclusively restricted
to dimeric Protein H (Figures 5C–D). We also determined that
bacterium-bacterium interactions via Protein H is temperature
dependent (Figure 6C).
Recently we showed that IgG binding to Protein H enhances
C4BP binding to Protein H (31). This was unexpected because
C4BP and IgG occupy overlapping binding sites on Protein H
and therefore one would expect a competition in binding between
the two proteins rather than the observed synergistic binding
(11, 15, 31). We found that human IgG-Fc specifically stabilizes
the dimeric structure of Protein H and therefore allows for
increased C4BP binding to the bacteria. Data presented here shed
light on the molecular details of how S. pyogenes Protein H uses
human IgG to capture more C4BP to evade complement.
C4BP is a molecule with seven identical α-chains and a unique
β-chain (23). The identified binding site for M proteins as well
as Protein H is localized to the N-terminus of the α-chain (11,
41, 42), which also contains the complement inhibitory site (43).
C4BP can interact with up to four C4b molecules (44). Earlier,
we reported that C4BP bound to S. pyogenes via Protein H is
still functional and can indeed act as a cofactor for Factor I thus
degrading C4b on the bacterial surface (11). Since C4BP can bind
only up to four C4b simultaneously, the remaining three α-chains
(arms) are available to interact with surface bound Protein H to
confer protection to S. pyogenes. Testing the complex of Protein
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H, IgG and C4BP for cofactor activity to Factor I in vitro is not
feasible, since the complex immediately precipitates. However,
the fact that the FI-cofactor activity of C4BP is retained when
bound to bacterial surfaces as well as in complexes, for example
with DNA, suggests that the C4BP-IgG-Protein H complex will
also have cofactor activity (45–47).
These immunocomplexes between C4BP, IgG, and Protein
H may also be formed after a cleavage of Protein H from the
surface of S. pyogenes. The bacteria express a soluble virulence
factor, SpeB, which is a promiscuous cysteine protease, which
releases Protein H from the surface. The 36 kDa fragment of
Protein H that is released binds IgG and given the overlapping
nature of the IgG and C4BP binding sites, it is also likely to
bind C4BP (48). It was proposed, that shedding of Protein
H and M proteins promote spreading of infection and could
contribute to post-streptococcal glomerulonephritis (48, 49). The
large complexes formed between the released fragment of Protein
H, IgG, and C4BP could support the formation of microthrombi
during streptococcal infections, one of the hallmarks of systemic
streptococcal infections (50, 51).
The gene for Protein H lies adjacent to the M protein
gene, and presumably has evolved by gene duplication (52).
Similar to M proteins, Protein H also presents a coiled-coil
dimer structure with a heptad repeat pattern (28). Protein H
dimers are stabilized by low temperatures; Protein H exists
as a monomer above 37◦C, indicating low thermal stability
(Figure 5A). This dimeric structure however seems to be a
prerequisite for binding to human protein ligands. Monomeric
Protein H does not only form homodimers, but it can bind
itself and M1 in an antiparallel manner (28). This is believed to
facilitate interactions with adjacent bacteria, or even with host
cells (35). Thus, in this fashion, the Protein H structure may
influence host pathogen interactions. Interestingly, addition of
ligands, such as albumin or human IgG significantly increases the
stability of Protein H dimers (28). Of note, IgG does not bind to
purified monomeric Protein H at temperatures above 37◦C, and
therefore does not induce dimer formation at supra-physiologic
temperatures (30).
In addition to Protein H, other streptococcal IgG binding
proteins such as Arp4, Sir and M1 also bind IgG only below 37◦C
(30, 53). Notably, all these biochemical studies were performed
with purified proteins. We recently showed that on the bacterial
surface, Protein H binds IgG even at 37 and 39◦C (31). This may
be related to anchoring of the protein to the bacterial surface as
well as the density of Protein H, or to other proximate proteins.
All those factors may influence the conformation of Protein H.
These variables are absent when analyzing isolated Protein H and
could explain contradictory results when using purified proteins
vs. proteins in situ.
Why C4BP binding to S. pyogenes AP1 peaks at IgG levels
of 1 mg/ml instead of the physiological serum concentration
of 10–15 mg/ml remains unclear (Figure 6E). One hypothesis
is that IgG-Fc directed binding competes with Fab directed
binding (of whole IgG) to Protein H. However, we previously
showed that human IgG exclusively binds to Protein H via
Fc domains and not through the antigen recognition sites on
the antibody (Figure 1D) (31). By comparing F(ab), Fc, and
whole IgG binding to Protein H, we only observed background
binding to F(ab) independent on the amounts used (31). Thus,
it does not appear to be a direct competition, probably due
to the lack of anti-M/H protein antibodies. Considering the
hypervariability of M proteins, including Protein H, it seems
plausible that only very little antibodies from a pool of >1,000
people can bind isolated Protein H from S. pyogenes AP1
(29, 54). This hypervariability is also one of the main reasons
why a broadly protective vaccine against S. pyogenes remains
elusive (55). A more likely explanation why C4BP binding
peaked at 1 mg/ml IgG is orientation of the antibody on the
bacteria. It was shown that streptococci bind polyclonal human
immunoglobulins predominantly via their Fc region in the
presence of low IgG concentrations, but at high (e.g., 10 mg/ml)
concentrations Fab binding dominates, because a small fraction
of the IgG in human sera IVIG contains IgGwhose Fab is directed
against bacteria (56). Of note, Fab binding occurs rather to whole
bacteria, but not to Protein H itself. This also explains why the
human mAb denosumab did not block C4BP binding even at 10
mg/ml (Figure 6E). If the bacteria are covered with antibodies
bound via the Fab domains, the Fc domains cannot interact with
Protein H to stabilize the dimeric structure. That together with
the thermal instability of Protein H at physiological temperatures
explains the reduced C4BP binding.
Similar to IgG and C4BP binding to Protein H, we found
that the interaction between bacteria is also temperature-
dependent (Figure 6A). The majority of streptococcal infections
are suppurative infections such as pharyngitis and pyoderma,
which involve peripheral tissues with a temperature lower than
the body core temperature (5, 57). Lower temperatures and a
lower IgG level compared to those encountered in circulation
might support the stability of the M-protein family (M protein
and Protein H) and could explain streptococcal virulence
especially at cutaneous or mucosal surfaces. At temperatures
between 35 and 37◦C bacteria aggregated due to Protein H,
however at 41◦C no aggregation was observed despite the
presence of Protein H. This indicates, that the aggregation of
S. pyogenes AP1 and most likely other strains as well-depend
on the homophilic anti-parallel interactions between Protein H
dimers and similar proteins to form a Protein H- Protein H
homo-tetramer. This tetramerization could be interrupted not
only through the AHP peptide (35), but also by temperature.
Of note, the AHP peptide preferably binds Protein H dimers
and thus interferes with tetramerization. Only at a 1,000-fold
molar excess Frick et al. observed <50% monomerization of
Protein H. Another effect of AHP is the increase of C4BP binding
to S. pyogenes (Figure 6C). The peptide interrupts Protein H
dimer-dimer interactions between bacteria, but not Protein H
dimer formation. We hypothesize that the peptide renders more
binding sites available for C4BP, which were previously blocked
by Protein H-Protein H interactions (Figure 6C).
High fevers caused by streptococcal infections may induce
monomerization of Protein H/M protein, which in turn could
curtail the invasive capacity of the bacteria and reduce immune
evasion (58). Thus, the febrile response may help the immune
system counteract this bacterial virulence mechanism and
support bacterial clearance. We found that in the absence of IgG,
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C4BP binding decreased with increasing temperature (schematic
representation in Figure 7A). Compared to 30◦C, and beginning
at 37◦C, <50% of C4BP binding was observed. This effect was
reverted in the presence of IgG; C4BP binding to S. pyogenes
was maximal at all measured temperatures (31). Thus, it appears
that monomerization does not occur in an all-or-nothing fashion,
but rather gradually peaking at 41◦C with 100% of Protein H
being in a monomeric form (Figure 5A). Taken together, IgG
seems to counteract Protein H monomerization on S. pyogenes
by stabilizing Protein H at higher temperatures (Figure 7B),
leading to more C4BP binding and increased resistance to
complement. The molecular reason might be the stabilized
dimeric coiled-coil structure of Protein H preventing dissociation
into monomers, thereby enabling it to retain its capacity to
bind ligands.
Taken together, targeting Protein H to prevent dimerization
would reduce C4BP binding and enable increased complement
deposition to clear the bacteria. This could be possible at
any given temperature, so that the effect of fever is not a
prerequisite. Another therapeutic approach would be to target
the Protein H-IgG interaction, because a lack of IgG binding
would monomerize Protein H and again reduce C4BP binding—
this modality would be effective in febrile conditions, where the
Fc domain of IgG stabilizes Protein H dimers. That way, even
bacterial aggregates would be targeted, which are important for
virulence and colonization (Figure 7C) (35).
Here we provide explanation and a physiological function for
IgG binding proteins, which contributes to improved survival of
S. pyogenes and an advantage for the bacteria in the ongoing and
evolving struggle between the host and pathogen.
CONTRIBUTION TO THE FIELD
STATEMENT
Streptococcus pyogenes (GAS), an exclusively human pathogen,
affects over 700 million people worldwide annually. GAS has
evolved several mechanisms to avoid host immune surveillance.
In one such strategy, Protein H, a member of the M protein
surface adhesin family, binds human IgG via its Fc-domain,
thereby subverting opsonophagocytosis. We previously showed
that a second effect of Protein H-IgG Fc interactions was to
enhance recruitment of the soluble complement inhibitor, C4b-
binding protein (C4BP). Increased C4BP acquisition by GAS
prevents efficient complement activation and reduces phagocytic
clearance. Herein, we elucidate the molecular mechanism of
this observation. We show that dimerization of Protein H is
required for IgG Fc binding. IgG stabilizes Protein H dimers at
body core temperatures and allows stable interactions with C4BP.
Protein H, IgG Fc, and C4BP form a stable tripartite structure.
Importantly, this phenomenon occurs at low IgG concentrations,
as may be encountered in extravascular compartments. In
contrast, enhanced C4BP binding is abolished when IgG Fab
interacts with Protein H, as observed with pooled human IgG.
This knowledge can be harnessed to develop novel treatments
andmay also explain the clinical utility of intravenous IgG (IVIG)
therapy for certain GAS infections.
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